<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The addition of rituximab to <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi> and <z:chebi fb="2" ids="8378">prednisolone</z:chebi> (CVP) for advanced follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> increases median time to progression by 17 months </plain></SENT>
<SENT sid="1" pm="."><plain>A US societal cost-effectiveness of R-CVP versus CVP is estimated for a representative 50-year-old patient </plain></SENT>
<SENT sid="2" pm="."><plain>Progression-free survival (PFS) and overall survival are based on a randomized Phase III trial </plain></SENT>
<SENT sid="3" pm="."><plain>Costs are estimated using Medicare reimbursement rates and published drug price data, and include drug and administration costs, adverse events, treatment of relapses, and end-of-life care </plain></SENT>
<SENT sid="4" pm="."><plain>Utility estimates are derived from the literature and a 3% discount rate is employed </plain></SENT>
<SENT sid="5" pm="."><plain>Mean overall survival is projected to be 1.51 years longer for patients assigned to R-CVP versus CVP </plain></SENT>
<SENT sid="6" pm="."><plain>The cost per quality-adjusted year of life gained is $28,565 </plain></SENT>
<SENT sid="7" pm="."><plain>The utility associated with stable or progressive disease and the unit drug cost of rituximab most influence the findings </plain></SENT>
<SENT sid="8" pm="."><plain>The cost-effectiveness ratio of R-CVP compared with CVP is projected to be cost-effective in the United States under a range of sensitivity analyses </plain></SENT>
</text></document>